Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration  by Lacour, Bernard et al.
Kidney International, Vol. 67 (2005), pp. 1062–1069
Chronic renal failure is associated with increased tissue
deposition of lanthanum after 28-day oral administration
BERNARD LACOUR, ANTHONY LUCAS, DANIEL AUCHE`RE, NADYA RUELLAN,
NATALIE MARIAUD DE SERRE PATEY, and TILMAN B. DRU¨EKE
Laboratoire de Biochimie A, Hoˆpital Necker, Paris and Laboratoire de Physiologie, Faculte´ de Pharmacie, Chaˆtenay-Malabry,
France; Inserm Unit 507 and Division of Nephrology, and Service d’Anatomie Pathologique, Hoˆpital Necker, Paris, France
Chronic renal failure is associated with increased tissue deposi-
tion of lanthanum after 28-day oral administration.
Background. Lanthanum (La) carbonate has recently been
proposed as an alternative, calcium- and aluminum-free phos-
phate binder for the treatment of hyperphosphatemia of chronic
renal failure (CRF). However, the extent to which CRF en-
hances tissue La accumulation induced by oral La overload
above that observed under conditions of normal renal function
remains a matter of debate. In the present study, we examined
this issue in two different rat models of CRF.
Methods. In a first series of experiments, adult male Sprague-
Dawley rats received either a diet to which 0.3% adenine (wt%
in feed) was added to induce CRF (“chemical CRF,” N = 20),
or a diet free of adenine (control, N = 16). In a second series
of experiments, adult male Sprague-Dawley rats underwent 5/6
nephrectomy in a two-step procedure (“surgical CRF,” N = 24).
Half of all CRF and control rats were exposed to dietary La (3%
lanthanum carbonate, wt% in feed) for four weeks (La[+] rats),
whereas the other half received a placebo (La[–] rats).
Results. At the end of this time period, creatinine clearance
was 1.51 ± 0.15 (mean ± SEM) and 1.45 ± 0.11 mL/min in La[–]
control and La[+] control rats, and declined to 0.22 ± 0.03 and
0.31 ± 0.03 mL/min in La[+]-adenine-CRF and La[+]-Nx-CRF
rats, respectively. Urinary La excretion was 0.025 ± 0.010 lg/
24 hr in La[–] control rats. It increased to 4.9 ± 1.2, 17 ± 3.8,
and 77 ± 18 lg/24 hr in La[+] control, La[+]-adenine-CRF, and
La[+]-Nx-CRF rats, respectively. However, only the last value
was significantly different from control value. Tissue La concen-
tration was increased in La[+] control rats compared with La[–]
control rats. More importantly, tissue La concentration was
strikingly higher in La[+]-CRF rats than in La[+] control rats.
Thus, liver La (ng/g dry wt) was 1173 ± 148 in La[+]-adenine-
CRF and 1742 ± 158 in La[+]-Nx-CRF rats, respectively, com-
pared with 385 ± 29 in La[+] control rats (P < 0.001), and 7.0 ±
1.4 in La[–] control rats; similarly, bone La was 230 ± 14 and
288 ± 26 compared with 81 ± 8, respectively (P < 0.001), ver-
sus 27 ± 4 in La[–] control rats. Comparable differences were
observed in the kidney, skeletal muscle, myocardium, lung, and
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brain, although to different extents in La[+]-adenine-CRF com-
pared with La[+]-Nx-CRF rats. Finally, liver and kidney weight
was significantly reduced in La[+]-adenine-CRF rats compared
with La[−]-adenine-CRF rats.
Conclusion. The oral administration of lanthanum carbonate
to normal rats leads to a more than 10-fold increase of tissue
La content in at least some organs, including the liver, lung,
and kidney. This increase is further enhanced by the uremic
state, per se. Plasma levels are a poor indicator of tissue burden.
Given the dramatic tissue levels obtained with this rare earth
metal given by the oral route, particularly in liver for absolute
values, it is probable that the stimulation by CRF is at least
partially explained by an increase in intestinal La absorption.
The absorptive pathways involved in intestinal La absorption
require further study, including possibly enhancing conditions.
Important clinical data has continued to emerge out-
lining the need to aggressively control blood levels of P
(phosphorus), Ca (calcium), and PTH (parathyroid hor-
mone) in chronic kidney disease (CKD) and chronic renal
failure (CRF). The significance of the data has resulted
in guidelines issued by the National Kidney Foundation
[1]. This has presented physicians with the challenge of
how to best manage patients pharmacologically. The im-
portance of controlling blood P while not disturbing cal-
cium homeostasis has brought into question the use of
large amounts of calcium-based phosphate binders in the
context of progression of vascular calcification in this pa-
tient population [2–4]. In addition, vascular and valvu-
lar calcification is present and often severe long before
progression to end-stage renal disease (ESRD) in nondi-
alyzed individuals with [5] or without [6] diabetic renal
disease. At present, only sevelamer, a nonmetal and non-
absorbed polymeric-based phosphate binder, has been
shown to both control plasma phosphorus without dis-
turbing plasma calcium levels and, in turn, decrease the
progression toward vascular and valvular calcification [2].
Lanthanum carbonate has been recently approved
in Sweden as a noncalcium, nonaluminum phosphate
binder. However, there continues to be concern regarding
the possibility of metal accumulation in tissues over time
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and possible long-term side effects. Taking heed of the
lessons learned with metal-based binders like aluminum,
it is important to be rigorous in the assessment of the
long-term health risks associated with metal accumula-
tion. In the context of increasing evidence of the need
to manage mineral metabolism adequately prior to the
need for dialysis, patients may be treated with phosphate
binders for significantly longer periods of time.
Animal studies examining lanthanum’s biodistribution
indicate that, upon entering the systemic circulation, it
can rapidly enter tissue compartments, with the liver be-
ing the organ of greatest accumulation [7]. Other more re-
cent studies in normal and CKD rats indicate that chronic
oral administration of lanthanum carbonate results in
substantial increases in tissue levels of lanthanum, with
the liver being the organ of greatest burden [abstracts;
Sacchiero R et al, J Am Soc Nephrol 14:205A, 2003; Dam-
ment SJP, Gill M, J Am Soc Nephrol 14:204A, 2003]. How-
ever, a long-term study in dialysis patients who were on
lanthanum carbonate treatment for 12 months did not
reveal adverse effects on bone turnover [8].
The extent to which CRF enhances lanthanum accumu-
lation in tissues has been an important question. There-
fore, experiments were conducted to examine whether
the modality of CRF induction or the uremic state, per
se, result in enhanced tissue accumulation of lanthanum.
We also wished to know whether lanthanum accumula-
tion was mainly due to increased intestinal absorption
or decreased urinary excretion. Two different rat mod-
els of CRF were chosen, that of adenine-induced renal
failure characterized by a progressive obstructive condi-
tion as a result of adenine crystal deposition in the kidney,
and the more widely used 5/6 nephrectomy/bipolar resec-
tion model. Our findings indicate that regardless of the
means of CRF induction, there is significantly greater tis-
sue deposition of lanthanum in the condition of CRF and
chronic oral administration of lanthanum carbonate than
under the condition of normal renal function, and that
enhanced intestinal uptake of lanthanum is probably the
mechanism by which uremia favors tissue accumulation.
METHODS
Animals and diets
Male Sprague-Dawley rats were obtained from IFFA-
Credo (Lyon, France). Rats used for the first set of
experiments (adenine-overloaded vs. control rats, see be-
low) had a body weight of approximately 350 g, and rats
used for the second set of experiments (surgical nephrec-
tomy model, see below) of approximately 300 g. Body
weight was checked twice weekly throughout the study.
Rats were housed in polycarbonate cages in a pathogen-
free facility set on a 12-hour light-dark cycle and given
free access to water. Upon arrival in the laboratory,
they were fed Teklad diet (ref. 2018S) containing 18.8%
protein, 57% carbohydrate, and 5.7% crude oil, 1.01%
calcium, 0.65% phosphorus, and 51lg/kg vitamin D. All
procedures were in accordance with National Institutes
of Health guidelines for the care and use of experimental
animals (NIH publication no. 85–23). The animals were
housed in groups of up to five.
Creation of chronic renal failure (CRF)
Two different types of CRF were used. In a first series of
experiments, CRF was created “chemically,” in that 0.3%
adenine was added to the diet for two weeks, leading to
a metabolic type of nephropathy resembling adenosine
phosphoribosyl transferase (APRT) deficiency (adenine-
CRF rats), according to Yokozawa et al [9], but using an
adenine content in diet of 0.3%, instead of 0.75%. Normal
male Sprague-Dawley rats served as control rats.
In a second series of experiments, CRF was created
“surgically” by a two-step procedure, consisting of bipo-
lar resection of right kidney, followed by left nephrectomy
one week later, thereby obtaining a state of 5/6 nephrec-
tomy, as reported previously [10]. All surgical procedures
were done under general isoflurane anesthesia.
Experimental procedure
Rats of the two groups of the first series were random-
ized into lanthanum (La) and placebo groups, receiv-
ing the above adenine-enriched diet or normal diet to
which either 3% lanthanum carbonate and 1.05% cellu-
lose (Sigma) (La[+]-adenine-CRF rats and La[+] control
rats) or 4.05% cellulose alone (La[–]-adenine-CRF rats
and La[–] control rats) was added. The diets were given
for 28 days. Lanthanum carbonate was purchased as La2
(CO3)3, 12 H2O (Alfa Alsan, lot no. Go2N26).
Rats of the second series were allocated into lan-
thanum and placebo groups three weeks after con-
tralateral nephrectomy, receiving the above adenine-free
Teklad diet, to which either 3% lanthanum carbonate and
1.35% cellulose as a placebo (Sigma) (La[+]-Nx-CRF
rats) or 4.35% cellulose alone as a placebo (La[–]-Nx-
CRF rats) was added. Before the end of the three weeks,
300 lL blood was sampled under isoflurane anesthesia
from jugular vein into preheparinized vials, and plasma
creatinine determined. Animals were allocated to one
group or the other based on plasma creatinine levels, to
achieve an even distribution of CRF between La[+]-Nx-
CRF rats and La[–]-Nx-CRF rats. The diets were fed for
28 days.
For the collection of urine, rats were housed in
metabolic cages on Friday of week 1 and urine was col-
lected from Tuesday through Thursday of week 2. On
Friday morning, in fasting state, 300 lL blood was sam-
pled as described above. The metabolic cage procedure
was repeated at weeks 3 and 4. Metabolic cage studies
were performed only in La[+] control rats (N =8), La[+]-
adenine-CRF rats (N =10), and La[+]-Nx-CRF rats (N =
11), and compared with La[–] control rats (N = 6).
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At the end of study, rats were held in fasting state
overnight, starting at 5 p.m., anesthetized by pentobar-
bital in the following morning, and a maximal amount
of blood drawn from the aorta into preheparinized vials.
Subsequently, organs and tissues were removed in the
following order: small intestine (jejunum), rinsed with
physiologic saline, and cut into small pieces placed in 10%
formaldehyde solution for light microscopy examination;
heart, lung, kidney, liver, brain, quadriceps muscle, and
both femurs.
Plasma and urine biochemistry
Plasma and/or urinary concentrations of urea, creati-
nine, total calcium, phosphorus, total protein, sodium,
potassium, and chloride were assessed using Hitachi 917
autoanalyzer (Roche, Meylan, France).
Light microscopy
Histologic examinations of small intestine were per-
formed using conventional techniques.
Lanthanum determination
Plasma, urine, and tissue samples were deep frozen im-
mediately (−20◦C). They were subsequently transferred
to Laboratoire De´partemental des Pyre´ne´es Atlantiques
(Lagor, France) for La analysis by inductively coupled
plasma atomic emission spectrometry (ICP-MS), accord-
ing to ISO 17294–2 (2003) norm, using UltraMass appa-
ratus (Varian, France), after mineralization of samples in
a closed microwave oven system (Ethos 1600; Milestone,
France), in presence of a mixture containing pure HNO3
and pure H2O2, 69%/30%, vol/vol.
Statistical analysis
Data were analyzed using analysis of variance
(ANOVA), followed by Newman-Keuls post-hoc test,
and presented as mean ± SEM. Differences between
groups were considered significant at the P < 0.05 level.
RESULTS
Body weight, organ weight, routine biochemistry,
and renal function
Figure 1A and B shows body weight over the 28-day
study period. Whereas body weight steadily increased in
La[–] control rats, it increased only slightly in La[–]-Nx-
CRF rats, during the second half of the study period,
and decreased slightly in La[–]-adenine-CRF rats. The
administration of lanthanum carbonate induced a mild
reduction in body weight gain in La[+] control rats, and a
slightly more marked reduction in La[+]-Nx-CRF and
La[+]-adenine-CRF rats. However, the observed differ-
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Fig. 1. Body weight changes in control and adenine-induced CRF rats
treated with lanthanum carbonate or placebo (A). Body weight changes
prior to and following 5/6 nephrectomy and treated with lanthanum
carbonate or placebo (B). Treatment groups: La[–] control, control rats
on placebo; La[+] control, control rats on La carbonate; La[–] Ad, rats
with adenine-induced chronic renal failure (CRF) on placebo; La[+]
Ad, rats with adenine-induced CRF on La carbonate; La[–] Nx-CRF,
rats with surgically-induced CRF on placebo; La[+] Nx-CRF, rats with
surgically-induced CRF on La carbonate. Data are expressed as mean
± standard error.
ences in body weight did not reach the level of statistical
significance.
The weight of several organs was decreased in CRF
rats compared to control rats (Table 1). The difference
persisted for liver, heart, lung, and femur when correct-
ing organ weight for femur length. The administration of
lanthanum induced a further reduction of organ weight
for liver (adenine-CRF) and kidney (adenine-CRF and
Nx-CRF), both in absolute terms and after correction for
femur length. Compared with normal control rats, kid-
ney weight was markedly increased in adenine-CRF rats,
whereas it was greatly reduced in Nx-CRF rats (note that
the total renal tissue in this model corresponded to the
partially nephrectomized kidney stump only).
Light microscopy of small intestine
Histologic examination of the jejunum led to the find-
ing of gross abnormalities in adenine-treated rats com-
pared to control rats (Fig. 2). The jejunal architecture was
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Table 1. Organ weights (wet weight)
Treatment groups N Brain mg Liver mg Heart mg Femur mg Lung mg Kidney mg
La[–] controla 8 2145 ± 15 11632 ± 390 1267 ± 46 825 ± 22 1444 ± 73 1489 ± 61
La[+] controlb 8 2085 ± 33 11004 ± 346 1273 ± 18 836 ± 14 1521 ± 57 1430 ± 36
La[–]-adenine-CRFc 10 1996 ± 51 9003 ± 374a 1000 ± 20a 735 ± 21a 1317 ± 82 2420 ± 136a
La[+]-adenine-CRFd 10 2025 ± 23 7114 ± 254ac 896 ± 33a 707 ± 24a 1167 ± 32a 2092 ± 163ac
La[–]-Nx-CRFe 9 1997 ± 35 8899 ± 254a 1329 ± 59 693 ± 21a 1182 ± 47a 810 ± 73a
La[+]-Nx-CRFf 11 2036 ± 31 7829 ± 394a 1170 ± 54 667 ± 14a 1188 ± 46a 727 ± 37ae
Treatment groups: La[–] control, control rats on placebo; La[+] control, control rats on La carbonate; La[–] adenine, rats with adenine-induced chronic renal failure
(CRF) on placebo; La[+] adenine, rats with adenine-induced CRF on La carbonate; La[–] Nx-CRF, rats with surgically-induced CRF on placebo; La[+] adenine, rats
with surgically-induced CRF on La carbonate. Data are expressed as mean ± standard error.
Superscript letters indicate significant difference to corresponding group (P < 0.01).
A B
C
Fig. 2. Jejunal villi of La[–] control rat (A)
and of La[–] adenine rat (B). Presence of ex-
tensive irregular white areas at the border
between enterocytes and submucosal layer.
Hematoxylin-eosin, ×10. Greater magnifica-
tion of two adjacent jejunal villi of La[–] ade-
nine rat (C). The irregular white areas appear
to extend from basal enterocyte aspect to sub-
mucosa. PAS, ×40.
respected, but large vacuoles were observed at the basal
pole of enterocytes all along the villous axis. The vac-
uoles were alcyan blue and periodic acid–Schiff negative.
No such changes were observed in rats with surgically
induced CRF (features not shown). The addition of lan-
thanum carbonate to the diet did not induce visible
changes of the jejunal wall (features not shown).
Table 2 shows plasma biochemistry values for crea-
tinine, urea, total protein, calcium, and phosphorus at
time of sacrifice. The increase in plasma urea and crea-
tinine during the lanthanum administration time period
was more marked in La[–]-adenine-CRF than in La[–]-
Nx-CRF rats (Table 3). In CRF rats receiving lanthanum
carbonate, a similar increase pattern was observed.
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Table 2. Plasma values after 28 days treatment with lanthanum carbonate or placebo
Treatment groups n Creatinine(lmol/L) Urea (mmol/L) Protein (g/L) Calcium (mmol/L) Phosphorus (mmol/L)
La[–]-controla 8 57 ± 2 6.7 ± 0.8 60.7 ± 1.4 2.45 ± 0.05 3.20 ± 0.15
La[+]-controlb 8 57 ± 1 6.8 ± 0.2 60.5 ± 0.8 2.66 ± 0.02 2.95 ± 0.08
La[–]-adenine-CRFc 10 295 ± 26 45.8 ± 3.9a 63.1 ± 1.3 2.80 ± 0.11a 4.67 ± 0.32a
La[+]-adenine-CRFd 10 280 ± 21 44.9 ± 3.4a 61.5 ± 0.9 3.19 ± 0.10ac 3.49 ± 0.25b
La[–]-Nx-CRFe 9 184 ± 12 42.1 ± 2.8a 55.0 ± 1.5 2.71 ± 0.12a 3.66 ± 0.09a
La[+]-Nx-CRFf 11 188 ± 14 40.9 ± 2.1a 58.2 ± 0.7 3.19 ± 0.14ae 2.30 ± 0.23ae
Treatment group abbreviations as in Table 1. Data are expressed as mean ± standard error.
Superscript letters indicate significant difference to corresponding group (P < 0.01)
Table 3. Plasma urea and creatinine concentrations of rats with chronic renal failure at start and end of treatment with either lanthanum
carbonate or placebo
Treatment groups Number of rats Plasma parameter Before End point Difference
La[–]-Nx-CRF N = 7 Creatinine lmol/L 150 ± 13 188 ± 14 38 ± 12
Urea mmol/L 36.1 ± 2.7 42.3 ± 3.3 6.2 ± 4.1
La[+]-Nx-CRF N = 9 Creatinine lmol/L 155 ± 10 188 ± 14 32 + 11
Urea mmol/L 34.3 ± 2.7 40.9 ± 2.1 6.7 ± 2.4
La[–]-adenine-CRF N = 9 Creatinine lmol/L 96 ± 6 295 ± 26 199 ± 23
Urea mmol/L 17.4 ± 1.3 45.8 ± 3.9 28.4 ± 3.3
La[+]-adenine-CRF N = 10 Creatinine lmol/L 91 ± 5 280 ± 21 189 ± 19
Urea mmol/L 16.5 ± 1.3 44.9 ± 3.4 28.3 ± 2.6
Treatment group abbreviations as in Table 1. Data are expressed as mean ± standard error.
At the end of the 4-week period of exposure to lan-
thanum carbonate or placebo, creatinine clearance was
1.51 ± 0.15 and 1.45 ± 0.11 mL/min in La[–] control
and La[+] control rats, respectively; it declined to 0.22 ±
0.03 mL/min (85%) and 0.31 ± 0.03 mL/min (79%)
in La[+]-adenine-CRF and La[+]-Nx-CRF rats, respec-
tively. Of note, urinary volume was markedly increased in
both La[+]-adenine-CRF and La[+]-Nx-CRF rat groups
compared with La[+] control rat group: 39.3 ± 3.1 and
35.5 ± 2.6 versus 8.7 ± 1.3 mL/24 hr.
Plasma total calcium levels were significantly increased
in La[+]-Nx-CRF and La[+]-adenine-CRF groups com-
pared with La[+] control group (Table 2). The levels
were identical for La[+]-Nx-CRF and La[+]-adenine-
CRF groups. Plasma phosphorus levels were lower in
all three rat groups receiving lanthanum than in corre-
sponding rat groups receiving placebo. Moreover, plasma
phosphorus was higher in La[+]-adenine-CRF than in
La[+]-Nx-CRF rats. There was no difference between
any group for plasma total protein and for plasma and
urinary sodium and potassium values, respectively (data
not shown).
Plasma La concentration and urinary La excretion
Plasma lanthanum levels at day 28, the day of sacrifice,
are shown in Figure 3A. There were no significant differ-
ences relative to control. At the end of the experiment,
urinary La excretion was very low in La[–] control rats
(Fig. 3B). It was nearly 200-fold higher in La[+] control
rats, and 660- to 2760-fold higher in La[+]-adenine-CRF
rats and La[+]-Nx-CRF rats, respectively (Fig. 3B).
Tissue La concentration
Figure 4A to G shows the concentration of La in vari-
ous tissues, expressed as ng/g dry weight. First, lanthanum
concentration was significantly increased in all organs of
La[+] control rats except brain and heart compared with
La[–] control rats. More important, tissue La concentra-
tion was significantly higher in La[+]-adenine-CRF rats
than in La[+] control rats for brain, liver, heart, lung, fe-
mur, and muscle, and significantly higher in La[+]-Nx-
CRF rats than in La[+] control rats for liver, femur,
and kidney. The highest absolute La concentrations were
recorded in liver, which were 3- to 5-fold increased in
CRF. The most marked increase brought about by CRF,
by nearly 10-fold, was observed in skeletal and heart
muscle of La[+]-Nx-CRF rats relative to La[+] control
rats. When comparing tissue La concentrations (per g dry
weight) of adenine-CRF rats with those of Nx-CRF rats,
those of liver, femur, and kidney were lower, where those
of muscle, heart, lung, and brain were higher.
DISCUSSION
It is clear that some percentage of lanthanum, when
administered to animals and humans via the oral route as
lanthanum carbonate, is absorbed from the intestine and
distributes in tissues. Debate has centered around how
much is absorbed, and under what conditions accumu-
lation becomes a matter of concern. Recently published
toxicology data in rats with normal renal function ad-
ministered lanthanum carbonate at doses up to 2000 mg/
kg/day for 80 weeks resulted in similar liver lanthanum
levels as that seen in CRF rats given a similar dose for just
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Fig. 3. Plasma (A) and urine (B) lanthanum levels following 28 days
treatment with lanthanum carbonate or placebo. Data are expressed as
mean ± standard error. Urine lanthanum excretion in 24 hours follow-
ing 28 days treatment with lanthanum carbonate or placebo (0.025 ±
0.01 lg/24hr, La[–] control; 4.85 ± 1.2 lg/24hr, La[+] control; 17 ± 3.8
lg/24hr, La[+]-adenine-CRF; 72 ± 18.5 lg/24hr, La[+]-Nx-CRF. Treat-
ment groups as in legend to Figure 1. Data are expressed as mean ±
standard error. ∗P < 0.01 for La[+] control vs. La[+]-Nx-CRF.
28 days [abstracts; Sacchiero R, et al, J Am Soc Nephrol
14:205A, 2003; Damment SJP, Gill M, J Am Soc Nephrol
14:204A, 2003]. Therefore, data suggests that the con-
dition of CRF imparts a unique predisposition toward
higher accumulation and/or retention of lanthanum in tis-
sues that is different than what occurs in healthy animals
and humans.
In the present study, we sought to confirm that it is
not the modality of CRF induction, per se, that results in
greater tissue accumulation of lanthanum, but the uremic
state itself. Therefore, we used two different experimen-
tal models to induce CRF in rats, namely the adenine
overload model and the surgical bipolar resection model.
Of interest, we observed major changes of small intestine
mucosa in the adenine model, but not the surgical model.
However, these changes did not appear to influence the
degree of transintestinal lanthanum transport because no
trend toward marked differences in lanthanum tissue ac-
cumulation between the two experimental models was
seen.
The dose of lanthanum used in these experiments
represented the dose of binder required to effectively
address the level of phosphate intake of the animals in
a normal feeding situation. Animals consumed approxi-
mately 180 mg/day elemental lanthanum and 300 mg/day
phosphate for 28 days.
Consistent with previously published data in rats [ab-
stract; Sacchiero R, et al, J Am Soc Nephrol 14:205A,
2003], we found that plasma levels of lanthanum were
a poor indicator of lanthanum in tissues. In addition,
lanthanum excretion in urine (24 hours) when calcu-
lated for that consumed was approximately 0.04% and
0.01% in the La[+]-Nx-CRF and La[+]-Ad-CRF groups,
respectively, compared with 0.0006% in La[+] control
group. Urinary lanthanum excretion was therefore, re-
spectively, 66 and 16 times higher in CRF rats than in
non-CRF rats on oral lanthanum supplementation. This
is approximately three orders of magnitude higher than
that described in normal healthy human subjects [ab-
stract; Fiddler G, et al, J Am Soc Nephrol 14:205A, 2003],
and may represent a fraction of what partitioned to tis-
sues in the 24-hour pass. The significant discrepancy in
these findings suggests important differences in the phar-
macokinetics of lanthanum in CRF, and warrants further
investigation.
CONCLUSION
It is not unreasonable to draw attention to the exten-
sive body of literature on aluminum for insight. It has
been well documented that the uremic condition is asso-
ciated with enhanced aluminum absorption. This increase
is believed to be associated with a variety of subtle mor-
phologic and functional changes that affect the integrity
of the normal intestinal barrier [11, 12]. In addition to
this, it has also been shown in studies with aluminum that
plasma levels are fraught with inaccuracy in attempting
to gauge intestinal absorption [13, 14]. Thus, if one exam-
ines here the urine lanthanum levels in the context of CRF
and the poor relationship to plasma levels, it suggests that,
without looking at tissue levels, it is not possible to pre-
dict deposition via the plasma. In addition, while there
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Fig. 4. Tissue lanthanum levels following 28 days treatment with lan-
thanum carbonate or placebo (A to G). Treatment groups as in legend
to Figure 1. Data are expressed as mean ± standard error. All statistical
comparisons to La[+] control. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.01.
were clearly increased levels of lanthanum detected in
bone, and this was enhanced 2- to 3-fold in the uremic
condition, increased lanthanum deposition in liver was
substantially greater. To the extent that bone metabolism
is different in CKD patients, the bone may also be an in-
sufficient means of predicting the extent of lanthanum
accumulation in the liver and elsewhere. These data un-
derscore the lack of knowledge in predicting lanthanum
absorption in the CKD population and its potential for
significant tissue deposition and toxicity.
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